# Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

> **NCT03342261** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 47 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Mixed Cryoglobulinemia

## Interventions

- **DRUG:** DAA treatment

## Key facts

- **NCT ID:** NCT03342261
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2017-11-01
- **Final completion:** 2017-11-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03342261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03342261, "Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03342261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*